AR107964A1 - Sal de adición de ácido de 1-(5-(2,4-difluorfenil)-1-((3-fluorfenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanmina - Google Patents

Sal de adición de ácido de 1-(5-(2,4-difluorfenil)-1-((3-fluorfenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanmina

Info

Publication number
AR107964A1
AR107964A1 ARP170100727A ARP170100727A AR107964A1 AR 107964 A1 AR107964 A1 AR 107964A1 AR P170100727 A ARP170100727 A AR P170100727A AR P170100727 A ARP170100727 A AR P170100727A AR 107964 A1 AR107964 A1 AR 107964A1
Authority
AR
Argentina
Prior art keywords
acid addition
addition salt
methylmethanmine
difluorfenil
fluorfenil
Prior art date
Application number
ARP170100727A
Other languages
English (en)
Original Assignee
Dae Woong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma
Publication of AR107964A1 publication Critical patent/AR107964A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente proporciona una sal de adición de ácido de 1-(5-(2,4-difluorfenil)-1-((3-fluorfenil)sulfonil)-4-metoxi-1H-pirrol-3-il)-N-metilmetanamina. La sal de adición de ácido arriba descripta puede tener no solo excelente actividad inhibitoria de la bomba protónica, actividad inhibitoria del daño gástrico y efecto mejorador de factores defensivos, sino, además, excelente actividad de erradicación contra H. pylori, y por lo tanto, puede usarse eficazmente para la prevención y el tratamiento de lesión gastrointestinal debida a Ulcera del tracto gastrointestinal, gastritis, esofagitis por reflujo, o H. pylori.
ARP170100727A 2016-03-25 2017-03-23 Sal de adición de ácido de 1-(5-(2,4-difluorfenil)-1-((3-fluorfenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanmina AR107964A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20160036081 2016-03-25

Publications (1)

Publication Number Publication Date
AR107964A1 true AR107964A1 (es) 2018-07-04

Family

ID=60141235

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170100727A AR107964A1 (es) 2016-03-25 2017-03-23 Sal de adición de ácido de 1-(5-(2,4-difluorfenil)-1-((3-fluorfenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanmina

Country Status (30)

Country Link
US (1) US10487053B2 (es)
EP (1) EP3433232B1 (es)
JP (1) JP6609065B2 (es)
KR (2) KR20170113040A (es)
CN (1) CN108602771B (es)
AR (1) AR107964A1 (es)
AU (1) AU2017238917B2 (es)
BR (1) BR112018069540A2 (es)
CA (1) CA3014753C (es)
CL (1) CL2018002415A1 (es)
CO (1) CO2018008834A2 (es)
DO (2) DOP2018000191A (es)
ES (1) ES2811478T3 (es)
HK (1) HK1254394A1 (es)
HR (1) HRP20201571T1 (es)
HU (1) HUE053741T2 (es)
JO (1) JOP20170071B1 (es)
MA (1) MA43832B1 (es)
MX (1) MX2018009220A (es)
MY (1) MY196355A (es)
NZ (1) NZ745267A (es)
PE (1) PE20190169A1 (es)
PH (1) PH12018501845A1 (es)
PL (1) PL3433232T3 (es)
PT (1) PT3433232T (es)
RS (1) RS60857B1 (es)
SG (1) SG11201806968RA (es)
SI (1) SI3433232T1 (es)
TN (1) TN2018000269A1 (es)
TW (1) TWI607753B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102081920B1 (ko) * 2016-03-25 2020-02-26 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형
KR102233455B1 (ko) * 2017-06-21 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
CA3157981C (en) * 2019-12-18 2024-03-26 Daewoong Pharmaceutical Co., Ltd. Liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine
KR20210156235A (ko) 2020-06-17 2021-12-24 일동제약(주) 신규한 산 분비 억제제 및 이의 용도
TW202241409A (zh) * 2020-12-18 2022-11-01 南韓商大熊製藥股份有限公司 包含1-(5-(2,4-二氟苯基)-1-((3-氟苯基)磺醯基)-4-甲氧基-1h-吡咯-3-基)-n-甲基甲胺之用於經口投予的新調配物
KR20230091056A (ko) * 2021-12-15 2023-06-22 일동제약(주) 1-설포닐 피롤 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물
WO2023113474A1 (ko) * 2021-12-15 2023-06-22 일동제약(주) 1-설포닐 피롤 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물
WO2023211843A1 (en) * 2022-04-25 2023-11-02 Daewoong Pharmaceutical Co., Ltd. Potassium-competitive acid blockers for the treatment of pathological hypersecretory conditions
TW202411216A (zh) * 2022-05-23 2024-03-16 南韓商日東製藥股份有限公司 ６－甲氧基吡啶－３－基衍生物之製造方法
TW202411215A (zh) * 2022-05-23 2024-03-16 南韓商日東製藥股份有限公司 ６－甲氧基吡啶－３－基衍生物之製造方法
CN117820193A (zh) * 2022-09-29 2024-04-05 安徽皓元药业有限公司 一种非苏拉赞盐酸盐晶型a及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2402362T3 (es) * 2004-09-30 2013-05-03 Takeda Pharmaceutical Company Limited Inhibidores de la bomba de protones
SI2327692T1 (sl) 2005-08-30 2012-11-30 Tekeda Pharmaceutical Company Ltd heterociklilsulfonil aminometil hetero arilno substituirani H pirolni derivati kot inhibitorji izločanja kisline
WO2007114338A1 (ja) * 2006-03-31 2007-10-11 Takeda Pharmaceutical Company Limited 酸分泌抑制薬
WO2008036211A1 (en) * 2006-09-19 2008-03-27 Alevium Pharmaceuticals, Inc. Prodrugs of proton pump inhibitors including the (1h-pyrrol-1-yl)-1h-benzimidazole moiety
US8933105B2 (en) * 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
BR112015010908A2 (pt) * 2012-11-19 2017-07-11 Jiangsu Hansoh Pharmaceutical Co Ltd derivado de pirrol sulfonamida, método de preparação para o mesmo e aplicação médica do mesmo
CN105143187B (zh) * 2013-02-28 2018-04-03 武田药品工业株式会社 制备磺酰氯化合物的方法
KR102084185B1 (ko) * 2013-08-29 2020-03-04 주식회사 대웅제약 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법
CN104447490B (zh) * 2014-11-19 2017-06-06 连云港恒运医药有限公司 一种质子泵抑制剂的晶型、制备中间体及其合成方法和医药用途
CN104447491B (zh) 2014-11-19 2017-06-23 连云港恒运医药有限公司 含吡咯环质子泵抑制剂的半富马酸盐及其中间体和医药用途
KR101613245B1 (ko) * 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물

Also Published As

Publication number Publication date
US20190031609A1 (en) 2019-01-31
HK1254394A1 (zh) 2019-07-19
US10487053B2 (en) 2019-11-26
CN108602771B (zh) 2021-07-16
MX2018009220A (es) 2018-09-10
NZ745267A (en) 2020-03-27
EP3433232A4 (en) 2019-07-31
SG11201806968RA (en) 2018-09-27
TWI607753B (zh) 2017-12-11
HRP20201571T1 (hr) 2020-12-11
ES2811478T3 (es) 2021-03-12
KR20170113040A (ko) 2017-10-12
PH12018501845B1 (en) 2019-05-15
PL3433232T3 (pl) 2020-12-14
TW201737908A (zh) 2017-11-01
BR112018069540A2 (pt) 2019-01-29
AU2017238917A1 (en) 2018-08-16
AU2017238917B2 (en) 2019-07-11
PH12018501845A1 (en) 2019-05-15
JP2019509320A (ja) 2019-04-04
CA3014753C (en) 2023-08-29
CO2018008834A2 (es) 2018-10-10
DOP2021000001A (es) 2021-03-15
RS60857B1 (sr) 2020-10-30
EP3433232A1 (en) 2019-01-30
SI3433232T1 (sl) 2020-10-30
JP6609065B2 (ja) 2019-11-20
JOP20170071B1 (ar) 2021-08-17
PE20190169A1 (es) 2019-02-01
PT3433232T (pt) 2020-07-21
CA3014753A1 (en) 2017-09-28
EP3433232B1 (en) 2020-07-15
CN108602771A (zh) 2018-09-28
MY196355A (en) 2023-03-24
TN2018000269A1 (en) 2020-01-16
MA43832B1 (fr) 2020-08-31
KR102417830B1 (ko) 2022-07-06
HUE053741T2 (hu) 2021-07-28
DOP2018000191A (es) 2018-09-30
KR20200105771A (ko) 2020-09-09
CL2018002415A1 (es) 2018-12-28

Similar Documents

Publication Publication Date Title
AR107964A1 (es) Sal de adición de ácido de 1-(5-(2,4-difluorfenil)-1-((3-fluorfenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanmina
DOP2021000213A (es) Derivados de 4-metoxi-pirrol novedosos o sales de los mismos y composición farmacéutica que comprende los mismos
PE20190170A1 (es) Nueva forma cristalina de sal de 1-(5-(2,4-difluorfenil)-1-(3-fluorfenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina
CL2020001754A1 (es) Derivado de amino-fluoropiperidina como inhibidor de quinasa.
CO2020007162A2 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
EA201890641A2 (ru) СТИМУЛЯТОРЫ sGC
NI201800086A (es) Métodos para tratar la depresión con antagonistas del recptor de orexina-2
PH12016501357B1 (en) Pharmaceutical preparation containing pyridylaminoacetic acid compound
AR094921A1 (es) Derivados de 2-acilaminotiazol o su sal
AR100748A1 (es) Derivado de 2-acilaminotiazol o su sal
AR090932A1 (es) Metodo para controlar plagas
EA201790453A3 (ru) Новая соль присоединения кислоты 1-(5-(2,4-дифторфенил)-1-((3- фторфенил)сульфонил)-4-метокси-1h-пиррол-3-ил)-n-метилметанамина
ECSP19051377A (es) Derivados de pirrolotriazina como inhibidor de cinasas
TH1801004904A (th) เกลือเพิ่มกรดแบบใหม่ของ 1-(5-(2,4-ไดฟลูออโรฟีนิล)-1-((3-ฟลูออโรฟีนิล)ซัลโฟนิล)-4-มีท็อกซี-1h-ไพร์โรล-3-อิล)-n-เมทิลมีเทนอะมีน
AR077854A1 (es) Combinaciones de compuestos activos
AR107164A1 (es) INHIBIDORES DE QUINASA p38
AR104947A1 (es) Composición de péptidos múltiples
RU2014125665A (ru) Способ наружного лечения микозов кожи
BR112018077078A2 (pt) composição para combater doenças do refluxo gastroesofágico
WO2018203751A8 (en) Therapeutic effects of guanabenz treatment in vanishing white matter
MD4520C1 (ro) N-(4-butoxifenil)-2-(piridin-2-ilmetiliden)hidrazincarbotioamida în calitate de inhibitor al proliferării celulelor T-47D ale cancerului mamar
EA202090926A1 (ru) Бензимидазольные соединения как сельскохозяйственные химические продукты
EA201991530A1 (ru) Композиции и способы лечения биопленок
RU2016121984A (ru) Способ восстановления почвенного плодородия